View all AJHO CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporter

This activity is funded by Physicians’ Education Resource®.

Best of the 31st Annual Miami Breast Cancer Conference®

Release Date: May 16, 2014 Expiration Date: May 16, 2015
Medium: Print with online posttest, evaluation, and request for credit


The optimal care of patients with breast cancer is rapidly changing as a result of advances in all aspects of patient care, including prevention, screening, and detection, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies. There is an increasing focus on providing multidisciplinary care for patients with complex diseases such as breast cancer through the use of integrated teams of professionals representing the relevant treatment modalities, including surgery, radiation therapy, and systemic medical interventions. The multidisciplinary Miami Breast Cancer Conference® has been bringing together surgical, medical, and radiation oncologists for 31 years, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging crossteam cooperation in the clinic. This article covers some of the more impactful presentations from the 31st Annual Miami Breast Cancer Conference®

Instructions For This Activity

  • Read the article in its entirety.

Instructions For Receiving Credit

  • In order to receive a CME certificate, participants must complete the posttest and pass with a score of 70% or higher, complete the evaluation, and request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

As a result of their participation in this activity, the target audience members should be better prepared to:

  1. Integrate current guidelines and recent data on local therapy, including new strategies for surgical and radiation therapy, into the treatment of patients with breast cancer.
  2. Incorporate biomarkers, molecular assays, and other risk assessment tools in treatment decision making for breast cancer when appropriate.
  3. Utilize optimal treatment based on patient characteristics, molecular data, and extent/aggressiveness of disease.
  4. Assess emerging clinical data regarding new agents and evolving strategies for the treatment of breast cancer.

Faculty Authors/Planners

Kimberly Blackwell, MD
Professor of Medicine
Assistant Professor in Radiation Oncology
Duke University School of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, NC
Disclosure: Institutional grant/research support (paid to Duke Cancer Institute): Roche/Genentech, Novartis, and Pfizer; consultant: Novartis, Sandoz, and Roche; speaker’s bureau: Genomic Health

Patrick I. Borgen, MD
Chairman, Department of Surgery
Maimonides Hospital
Director, Brooklyn Breast Cancer Program
Brooklyn, NY
Disclosure: Consultant: Genomic Health; speaker’s bureau: Genomic Health and Myriad Genetics

J. Michael Dixon, MD, OBE
Professor of Surgery & Consultant Surgeon
Clinical Director, Breakthrough Research Unit
Edinburgh Breast Unit
Edinburgh, UK
Disclosure: No relevant financial relationships with commercial interests.

Jay R. Harris, MD
Professor and Chair
Department of Radiation Oncology
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
Disclosure: No relevant financial relationships with commercial interests.

Lance A. Liotta, MD, PhD
University Professor
Co-Director, Center for Applied Proteomics & Molecular Medicine
Medical Director, Clinical Proteomics Lab
College of Science
George Mason University
Manassas, VA
Disclosure: Stock/shareholder: Theranostics Health

Joyce O'Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
The US Oncology Network Dallas, TX
Disclosure: Advisory board: Genentech Inc; consultant: Arno Therapeutics Inc, Eisai Inc, Genentech Inc, GlaxoSmithKline, Johnson & Johnson, sanofi-aventis US, Novartis Pharmaceuticals, Pfizer, Celgene Corporation, Corcept Therapeutics, and Med Fusion, LLC

Sunil Verma, MD, MSEd, FRCPC
Associate Professor
University of Toronto
Chair, Breast Medical Oncology
Sunnybrook Odette Cancer Centre
Toronto, ON
Disclosure: Grant/research support: sanofi-aventis and Roche; consultant: Novartis, Eli Lilly, Amgen, Roche, AstraZeneca, and Eisai

Medical Writer

Cheryl Zigrand
Disclosure: No relevant financial relationships with commercial interests.

The American Journal of Hematology/Oncology Editorial Board Members

Andrew Zelenetz, MD, PhD
Vice chair, Medical Informatics, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Research: Roche, GlaxoSmithKline, and Genentech; consultant: Seattle Genetics, sanofi-aventis US, GlaxoSmithKline, Gilead, Cephalon, and Celgene; scientific advisor: Cancer Genetics

David Ilson, MD, PhD
Medical oncologist, Gastroenterology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Consultant/advisory board: Lilly-Imclone, Amgen; grant/research support: Amgen, Bristol-Myers Sqiubb, Bayer; honoraria: Genentech

Staff Disclosures

Dru S. Dace, PhD, and Megan O'Connell: no relevant financial relationships with commercial interests.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.


The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By